LOC338667 Inhibitors
LOC338667 inhibitors encompass a range of compounds that target specific signaling pathways to indirectly affect the activity of LOC338667. Wortmannin and LY294002, as inhibitors of PI3K, are capable of impeding the formation of PIP3, a critical step for AKT activation, which is pivotal for a multitude of cellular survival and growth processes. Inhibition of this pathway can lead to a reduction in survival signals, which may correspondingly result in the inhibition of LOC338667 if it is associated with the PI3K/AKT pathway. PI3K/AKT is a pathway commonly involved in the regulation of cell proliferation, growth, and survival, and thus, manipulation of this pathway is likely to alter the activity of proteins that are involved in these processes.
Rapamycin, by inhibiting mTOR, particularly the mTORC1 complex, can suppress the processes of protein synthesis and cell growth, potentially decreasing the activity of LOC338667 if it is related to these cellular functions. Conversely, SB203580, PD98059, and U0126 inhibit the p38 MAPK and MEK/ERK signaling pathways, respectively. These pathways are integral to cellular stress responses, proliferation, and differentiation. Inhibitors within these pathways could decrease LOC338667 activity if it is a downstream effector. Additionally, SP600125 targets the JNK signaling pathway, which can influence the activity of transcription factors like AP-1; if LOC338667 is regulated by JNK signaling, itsactivity could be inhibited. Y-27632's action on ROCK inhibition may also lead to a reduction in LOC338667 activity by affecting the actin cytoskeleton organization, which is fundamental to cell shape and motility, implicating a potential connection if LOC338667 is involved in these processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor that prevents AKT activation by blocking PIP3 formation. As AKT can promote cell survival and growth, its inhibition by Wortmannin would lead to decreased survival signals, potentially diminishing LOC338667 activity if linked to growth factor signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Another PI3K inhibitor, LY294002 blocks the formation of PIP3, preventing AKT phosphorylation and activation. This could inhibit LOC338667 if it functions downstream of the PI3K/AKT pathway, which is involved in cell proliferation and survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that suppresses mTORC1 signaling. mTORC1 is involved in protein synthesis and cell growth, so inhibition by Rapamycin could decrease LOC338667 activity if it is associated with these cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor that can reduce the activity of proteins regulated by p38 MAPK signaling, involved in stress responses. If LOC338667 is activated by p38 MAPK, SB203580 would lead to its inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor that blocks ERK1/2 activation. Since ERK1/2 is involved in cell proliferation and differentiation, inhibition by PD98059 could lead to decreased LOC338667 activity if it operates within this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective MEK1/2 inhibitor, U0126 impairs ERK activation. LOC338667 activity could be inhibited by U0126 if LOC338667 functions are dependent on the MAPK/ERK signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can prevent the phosphorylation of c-Jun and the activation of AP-1 transcription factor. If LOC338667 is regulated by JNK signaling, SP600125 would result in its inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCK inhibitor that impedes actin cytoskeleton organization. If LOC338667 activity is related to cytoskeletal dynamics, inhibition by Y-27632 would lead to decreased activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Src family kinase inhibitor that hampers downstream signaling involved in cell adhesion and migration. LOC338667 inhibition could result from PP2 if it is part of signaling pathways involving Src kinases. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that targets Bcr-Abl and Src family kinases. Inhibition of these kinases by Dasatinib could lead to decreased LOC338667 activity if it is associated with tyrosine kinase signaling. | ||||||